Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252200
Status:
COMPLETED
Last Update Posted:
2009-09-23
First Post:
2005-11-10
Brief Title:
BNP Nesiritide vs Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Low Dose Continuous Infusion of BNP Nesiritide in the Prevention of Renal Insufficiency Post Cardiopulmonary Bypass Cardiac Surgery
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Use of BNP nesiritide vs placebo to help protect kidney function in patients undergoing heart bypass surgery
Detailed Description:
This is a randomized double-blind placebo controlled study of low dose nesiritide to prevent renal insufficiency after cardiopulmonary bypass surgery Patients included are those with greater than mild renal insufficiency preoperatively as defined by having a creatinine clearance of less than 50 mLminute determined by the Cockroft-Gault formula The infusion of nesiritide BNP 0005 mcgKgminute or placebo begins 1 hour before surgery and runs for 24 hours started after the induction of anesthesia prior to cardiopulmonary bypass
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None